|Mr. Peter Anastasiou||Exec. Vice Chairman||N/A||N/A||1960|
|Dr. Jerry Kanellos Ph.D.||Chief Operating Officer||N/A||N/A||1961|
|Dr. Gary S. Jacob||CEO & Director||N/A||N/A||1947|
|Mr. Phillip Allen Hains||CFO & Company Sec.||N/A||N/A||1959|
|Mr. David Lyon||Head of Marketing||N/A||N/A||N/A|
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.
Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.